Michael Fray

Title: The Innovative Contributions of Michael Fray

Introduction

Michael Fray is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic applications involving genetically engineered cells. His work focuses on enhancing the efficacy of treatments for various diseases.

Latest Patents

Michael Fray holds a patent for "Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof." This patent discloses genetically engineered hematopoietic cells that express one or more Krebs cycle modulating polypeptides. Additionally, it includes a chimeric receptor polypeptide capable of binding to a target antigen of interest. The engineered hematopoietic cells are designed for inhibiting cells that express a target antigen in subjects who require such treatment. He has 1 patent to his name.

Career Highlights

Michael Fray is currently associated with Sotio Biotech Inc., where he continues to push the boundaries of innovation in biotechnology. His work is instrumental in developing new therapeutic strategies that leverage the body's immune system to combat diseases.

Collaborations

Some of his notable coworkers include Kathleen McGinness and Seth Ettenberg, who contribute to the collaborative environment at Sotio Biotech Inc. Their combined expertise fosters a culture of innovation and advancement in the field.

Conclusion

Michael Fray's contributions to biotechnology through his innovative patent and work at Sotio Biotech Inc. highlight his role as a key figure in the development of advanced therapeutic solutions. His ongoing efforts continue to pave the way for future innovations in the industry.